Runt-related transcription factor 2 (RUNX2) mRNA (RUNX2 mRNA)

Runt-related transcription factor 2 (RUNX2) mRNA is the transcript of the RUNX2 gene, which encodes a master transcription factor essential for osteoblast differentiation and skeletal morphogenesis (UniProt Q13950). It plays a pivotal role in both intramembranous and endochondral ossification by regulating the expression of major bone matrix genes such as osteocalcin, type I collagen, and bone sialoprotein (NCBI Gene 860). Pathologically, mutations in the RUNX2 gene lead to cleidocranial dysplasia, a rare autosomal dominant skeletal disorder (PubMed 31434065). In oncology, RUNX2 mRNA is frequently overexpressed in various cancers, including osteosarcoma and metastatic breast and prostate cancers, where it promotes epithelial-mesenchymal transition (EMT), tumor cell invasion, and bone metastasis (PubMed 28213458). Therapeutic strategies targeting RUNX2 mRNA, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are being investigated to suppress its pro-tumorigenic activity. However, because RUNX2 is fundamental to bone homeostasis, therapeutic modulation requires careful consideration of potential adverse effects on skeletal integrity and repair.

Other names

CBFA1OSF2AML3Core-binding factor subunit alpha-1Osteoblast-specific transcription factor 2Acute myeloid leukemia 3 proteinCCDCLCDPEBP2A1

Inhibition of mRNA translation via RNA interference (siRNA) or antisense oligonucleotides (ASOs), or small molecule inhibition of the protein's DNA-binding activity.